COMP <GO>
BAX vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Baxter International Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BAX 3
— JNJ 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JNJ
LAST: $23.00 (-2.13%) • MKT CAP: $12.15B
balance-sheet
2.22
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BAX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BAX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.10% | 67.90% | -37.80 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.40% | 25.50% | -27.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.79% | 2.97% | -0.18 | JNJ | /fcf-yield <GO> |
| Operating Margin | -2.70% | 34.70% | -37.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -8.50% | 28.50% | -37.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 6.00% | -0.30 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.86% | 0.00% | +2.86 | BAX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.22 | 5.59 | -3.37 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.20% | -0.50 | BAX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.8 | 60.4 | -22.60 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.08 | -0.13 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 23.0x | -5.00 | BAX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.15B | $662.49B | -$650.34B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BAX REV | JNJ REV | BAX GROSS % | JNJ GROSS % | BAX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.24B | $94.19B | 30.1% | 67.9% | $339.0M | $19.70B |
| FY 2024 | $10.64B | $88.82B | 37.5% | 69.1% | $540.4M | $19.84B |
| FY 2023 | $10.36B | $85.16B | 44.0% | 44.0% | $1.26B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BAX // BETA 0.95
JNJ // BETA 1.08